Three men with type 2 diabetes used intermittent fasting to lose weight, lower their blood sugar levels and reverse their dependence on insulin treatment, according to a case study report published in The BMJ.

Socioeconomic factors—namely a mother’s insurance status and level of education—weigh heavily on Hispanic infants’ chances of surviving critical congenital heart disease (CHD) in their first year of life, a study out of the University of California, San Francisco suggests.

Direct oral anticoagulants (DOACs) can cut the short-term risk of thromboembolic events in half for patients who have undergone cardioversion of atrial fibrillation (AFib), suggests a meta-analysis published in the Journal of the American College of Cardiology.

For the first time, the World Health Organization (WHO) has included ambient noise from leisure-time activities in its guidelines on how cumulative exposure to high volumes can lead to health problems, including stress, hypertension and heart disease.

A genomic risk prediction tool developed by researchers in Australia and the U.K. has achieved greater risk discrimination than its predecessors while identifying patients at the highest and lowest likelihood of developing coronary artery disease (CAD), according to a study published ahead of print in the Journal of the American College of Cardiology.

When cardiologists get involved in the treatment of patients with a history of cancer and newly diagnosed atrial fibrillation (AFib), those people see a subsequent 11 percent reduction in the risk of stroke, according to a new study in the Journal of the American College of Cardiology. But those visits occur less often for that subgroup of patients than in AFib patients without cancer.

Rapidly growing rates of obesity and diabetes—already threats to global health—will likely have fatal consequences in the case of a future flu pandemic, the Telegraph reported this week.

The GALILEO trial has been stopped after an early look at outcomes revealed rivaroxaban was associated with greater odds of thromboembolic events, all-cause death and bleeding events compared to antiplatelet therapy following transcatheter aortic valve replacement (TAVR).